BeOne Medicines has signed a multi-part collaboration with Revolution Medicines to develop and commercialise targeted oncology therapies. They will be studied alongside Revolution Medicines’ RAS(ON) inhibitor assets, daraxonrasib; zoldonrasib; elironrasib; and RMC-5127. The agreement stipulates that Revolution Medicines will receive development and sales milestone payments, along with tiered royalties on net sales from these territories. BeOne will also be responsible for funding and conducting a global registrational Phase III trial for one of the Revolution Medicines’ RAS(ON) inhibitors, utilising its internal development resources. BeOne co-founder, chairman, and CEO John Oyler said: “We are pleased to enter this collaboration with Revolution Medicines, which gives BeOne the opportunity to evaluate combinations between assets from our oncology pipeline and four promising RAS(ON) inhibitors from Revolution Medicines.